D-Index & Metrics Best Publications

D-Index & Metrics

Discipline name D-index D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines. Citations Publications World Ranking National Ranking
Medicine D-index 116 Citations 51,228 757 World Ranking 1847 National Ranking 42

Overview

What is he best known for?

The fields of study he is best known for:

  • Internal medicine
  • Endocrinology
  • Diabetes mellitus

His main research concerns Internal medicine, Endocrinology, Insulin, Pancreatic hormone and Diabetes mellitus. Internal medicine is often connected to Type 2 diabetes in his work. His Type 2 diabetes research incorporates elements of Hypoglycemia and Placebo.

His study involves Insulin resistance, Glucagon secretion, Glucagon-like peptide-1, Glucagon and Islet, a branch of Endocrinology. As part of his studies on Insulin, he frequently links adjacent subjects like Pancreas. His research in Pancreatic hormone intersects with topics in Autonomic nervous system, Secretion and Bolus.

His most cited work include:

  • Interleukin-6-deficient mice develop mature-onset obesity. (985 citations)
  • Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus. (868 citations)
  • The high-fat diet-fed mouse: a model for studying mechanisms and treatment of impaired glucose tolerance and type 2 diabetes. (751 citations)

What are the main themes of his work throughout his whole career to date?

Internal medicine, Endocrinology, Insulin, Glucagon and Diabetes mellitus are his primary areas of study. His work in Internal medicine is not limited to one particular discipline; it also encompasses Type 2 diabetes. His Endocrinology study frequently draws connections to other fields, such as Neuropeptide.

His Insulin research includes themes of Carbachol and Secretion. He combines subjects such as Somatostatin and Peptide hormone with his study of Glucagon. His work focuses on many connections between Insulin resistance and other disciplines, such as Leptin, that overlap with his field of interest in Body mass index.

He most often published in these fields:

  • Internal medicine (91.60%)
  • Endocrinology (88.05%)
  • Insulin (53.25%)

What were the highlights of his more recent work (between 2010-2021)?

  • Internal medicine (91.60%)
  • Endocrinology (88.05%)
  • Insulin (53.25%)

In recent papers he was focusing on the following fields of study:

Bo Ahrén mainly investigates Internal medicine, Endocrinology, Insulin, Type 2 diabetes and Diabetes mellitus. Bo Ahrén regularly ties together related areas like Dipeptidyl peptidase-4 in his Internal medicine studies. Postprandial, Glucagon secretion, Glucagon-like peptide-1, Islet and Hormone are the subjects of his Endocrinology studies.

The study incorporates disciplines such as Liraglutide and Ingestion in addition to Insulin. Bo Ahrén has included themes like Metformin, Placebo and Pharmacology in his Type 2 diabetes study. His work deals with themes such as Secretion, Insulin oscillation and Glucagon-like peptide 1 receptor, which intersect with Glucagon.

Between 2010 and 2021, his most popular works were:

  • Dipeptidyl peptidase-4 inhibitors and cardiovascular risk: a meta-analysis of randomized clinical trials (216 citations)
  • Advancing Basal Insulin Replacement in Type 2 Diabetes Inadequately Controlled With Insulin Glargine Plus Oral Agents: A Comparison of Adding Albiglutide, a Weekly GLP-1 Receptor Agonist, Versus Thrice-Daily Prandial Insulin Lispro (168 citations)
  • HARMONY 3: 104-week randomized, double-blind, placebo- and active-controlled trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride in patients with type 2 diabetes taking metformin. (168 citations)

In his most recent research, the most cited papers focused on:

  • Internal medicine
  • Diabetes mellitus
  • Endocrinology

Bo Ahrén mainly focuses on Internal medicine, Endocrinology, Type 2 diabetes, Insulin and Diabetes mellitus. Bo Ahrén works mostly in the field of Internal medicine, limiting it down to topics relating to Dipeptidyl peptidase-4 and, in certain cases, Enzyme. Glucagon, Postprandial, Insulin resistance, Glucagon secretion and Glucagon-like peptide-1 are subfields of Endocrinology in which his conducts study.

His Type 2 diabetes research is multidisciplinary, incorporating perspectives in Hypoglycemia, Randomized controlled trial, Gastroenterology and Weight loss. Pancreatic hormone, Glycogen and Glucokinase is closely connected to Triglyceride in his research, which is encompassed under the umbrella topic of Insulin. The concepts of his Diabetes mellitus study are interwoven with issues in Oral administration, Carbohydrate metabolism and Crossover study.

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

Interleukin-6-deficient mice develop mature-onset obesity.

Ville Wallenius;Kristina Wallenius;Bo Ahrén;Mats Rudling.
Nature Medicine (2002)

1355 Citations

The high-fat diet-fed mouse: a model for studying mechanisms and treatment of impaired glucose tolerance and type 2 diabetes.

Maria Sörhede Winzell;Bo Ahrén.
Diabetes (2004)

1195 Citations

Autonomic regulation of islet hormone secretion--implications for health and disease.

B. Ahrén.
Diabetologia (2000)

1156 Citations

Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus.

M Gutniak;C Orskov;J J Holst;B Ahrén.
The New England Journal of Medicine (1992)

1059 Citations

Inhibition of Dipeptidyl Peptidase-4 Reduces Glycemia, Sustains Insulin Levels, and Reduces Glucagon Levels in Type 2 Diabetes

Bo Ahrén;Mona Landin-Olsson;Per-Anders Jansson;Maria Svensson.
The Journal of Clinical Endocrinology and Metabolism (2004)

968 Citations

Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease

Thomas Nyström;Mark K. Gutniak;Qimin Zhang;Fan Zhang.
American Journal of Physiology-endocrinology and Metabolism (2004)

780 Citations

Twelve- and 52-Week Efficacy of the Dipeptidyl Peptidase IV Inhibitor LAF237 in Metformin-Treated Patients With Type 2 Diabetes.

Bo Ahrén;Ramon Gomis;Eberhard Standl;David Mills.
Diabetes Care (2004)

733 Citations

Islet Amyloid and Type 2 Diabetes Mellitus

Jo W.M. Höppener;Bo Ahrén;Cornelis J.M. Lips.
The New England Journal of Medicine (2000)

653 Citations

FOXC2 Is a Winged Helix Gene that Counteracts Obesity, Hypertriglyceridemia, and Diet-Induced Insulin Resistance

Anna Cederberg;Line M. Grønning;Bo Ahrén;Kjetil Taskén.
Cell (2001)

632 Citations

Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes.

Bo Ahrén;Erik Simonsson;Hillevi Larsson;Mona Landin-Olsson.
Diabetes Care (2002)

618 Citations

Best Scientists Citing Bo Ahrén

Jens J. Holst

Jens J. Holst

University of Copenhagen

Publications: 359

Carolyn F. Deacon

Carolyn F. Deacon

University of Copenhagen

Publications: 112

Filip K. Knop

Filip K. Knop

University of Copenhagen

Publications: 111

Peter R. Flatt

Peter R. Flatt

University of Ulster

Publications: 100

Daniel J. Drucker

Daniel J. Drucker

Lunenfeld-Tanenbaum Research Institute

Publications: 99

Sten Madsbad

Sten Madsbad

Copenhagen University Hospital

Publications: 91

Michael A. Nauck

Michael A. Nauck

Ruhr University Bochum

Publications: 83

David A. D'Alessio

David A. D'Alessio

Duke University

Publications: 81

Bente Klarlund Pedersen

Bente Klarlund Pedersen

University of Copenhagen

Publications: 71

Giovanni Pacini

Giovanni Pacini

National Academies of Sciences, Engineering, and Medicine

Publications: 64

Michael Horowitz

Michael Horowitz

University of Adelaide

Publications: 61

Per-Olof Berggren

Per-Olof Berggren

Karolinska Institute

Publications: 58

Frank Sundler

Frank Sundler

Lund University

Publications: 58

Patrik Rorsman

Patrik Rorsman

University of Oxford

Publications: 54

Mark A. Febbraio

Mark A. Febbraio

Monash University

Publications: 53

Ralph A. DeFronzo

Ralph A. DeFronzo

The University of Texas Health Science Center at San Antonio

Publications: 51

Profile was last updated on December 6th, 2021.
Research.com Ranking is based on data retrieved from the Microsoft Academic Graph (MAG).
The ranking d-index is inferred from publications deemed to belong to the considered discipline.

If you think any of the details on this page are incorrect, let us know.

Contact us
Something went wrong. Please try again later.